U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06838962) titled 'Anti-CD38 Antibody Treating Primary Immune Thrombocytopenia (ITP)' on Jan. 07.
Brief Summary: To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of primary immune thrombocytopenia in patients who have failed first-line treatment.
Study Start Date: Aug. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Treatment
Intervention:
DRUG: Daratumumab Injection
intravenous Daratumumab administration
This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.
...